Health Related Quality of Life, Thyroid Cancer, Tyrosine Kinase Inhibitor
Conditions
Keywords
HRQOL, thyroid cancer, targeted therapy, Tyrosine kinase inhibitor
Brief summary
The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).
Detailed description
Surgical resection is the cornerstone of treatment for thyroid cancer. However, some patients present with locally advanced disease at the time of diagnosis, and they are not eligible for radical resection. Another patients still had the risk of recurrence after surgery, endocrine therapy and iodine-131 treatment. Tyrosine kinase inhibitors (TKI) have been proved to be effective in thyroid cancer patients. However, it was still unclear whether TKI drugs had influence on the HRQOL of LATC patients. The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).Participants enroll the study after informed consent, and quality of life will be assessed using quality of life questionnaires EORTC QLQ C30, and EORTC THY 47 before surgery, and 1,3,6 and 12 months after treatment.
Interventions
DRUGTyrosine kinase inhibitor drugs.
TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
Sponsors
Fujian Cancer Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Inclusion criteria
* Patients age (18-70 year old) * Diagnosis of locally advanced thyroid cancer * Patient receiving TKI drugs.
Exclusion criteria
* pregnancy or breastfeeding women; * history of other malignant diseases, unstable angina, myocardial infarction, cerebral infarction or cerebral hemorrhage within 6 months; (3) patients missing questionnaires greater than 3 times.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the global status of QLQ C30 questionnaire | 1 year | Change in global HRQOL score between baseline and at 12 months after treatment. A change of more than 10% is set as a limit for a significant change |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adversed events of TKI. | 1 year | all TKI-related adversed events during and after the treatment of TKI. |
| Change in fatigue score | 1 year | Change in fatigue score between start and at 12 months after thyroid treatment. A change of more than 10% is set as a limit for a significant change. |
Countries
China
Contacts
Primary Contactyu wu, doctor
Outcome results
None listed